Navigation Links
Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation

EAST BRUNSWICK, N.J., July 23, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Delaware Court of Chancery has issued a bench ruling granting both of Savient's motions in the lawsuit brought against the Company by Tang Capital Partners, LP and certain other holders of Savient's convertible notes.  The Court of Chancery decided that the plaintiff noteholders do not have standing to bring an action to appoint a receiver for Savient and that an event of default has not occurred under Savient's convertible notes. The Court has not yet come to a conclusion on the plaintiff's claims for breach of fiduciary duty and waste.  Savient continues to believe that all outstanding claims alleged by the plaintiffs are without merit, and intends to vigorously defend this lawsuit to its completion.  The Court of Chancery's decision is subject to appeal by the plaintiffs.  In addition, Savient's claim for damages against Tang Capital remains outstanding. 

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").
Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at

Contact:Mary ColemanKelly Sullivan / Taylor Ingraham Savient Pharmaceuticals, Inc.Joele Frank, Wilkinson Brimmer / (732) 418-93(212) 355-4449  


SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
3. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
4. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
(Date:11/25/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of ... Antonius Schuh, Ph.D., is scheduled to present a corporate ... Healthcare Conference. th Annual Piper Jaffray ... New York on Tuesday, December ... be available for one-on-one meetings during the conference. The ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... Additional breast cancers found with MRI ... to a study published online in the journal Radiology. Researchers said that in ... a change in treatment. , Breast MRI is the most sensitive technique for ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is ... pleasing the palates of attendees is of the utmost importance. Whether you are ... get-together, give these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... 2015 , ... Medical Solutions, one of the nation’s top ... culture with the company’s Cincinnati office being named a finalist among greater Cincinnati’s ... a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best Places to ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, ... of Connecticut on behalf of a home health care worker who provided companionship services ... home health care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge ...
Breaking Medicine News(10 mins):